Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 5
1997 1
1998 5
1999 4
2000 2
2001 4
2002 9
2003 6
2004 8
2005 5
2006 6
2007 4
2008 3
2009 7
2010 13
2011 5
2012 7
2013 7
2014 8
2015 7
2016 11
2017 16
2018 13
2019 13
2020 22
2021 23
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

197 results
Results by year
Filters applied: . Clear all
Page 1
The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review.
Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, Bramer W, van Puijenbroek E, Hazes JMW, Te Winkel B. Perez-Garcia LF, et al. Among authors: van puijenbroek e. Hum Reprod Update. 2020 Nov 1;26(6):961-1001. doi: 10.1093/humupd/dmaa022. Hum Reprod Update. 2020. PMID: 32743663 Free PMC article.
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P. Mössner E, et al. Among authors: van puijenbroek e. Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1. Blood. 2010. PMID: 20194898 Free PMC article.
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Among authors: van puijenbroek e. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
Mirtazapine-induced arthralgia.
Passier A, van Puijenbroek E. Passier A, et al. Among authors: van puijenbroek e. Br J Clin Pharmacol. 2005 Nov;60(5):570-2. doi: 10.1111/j.1365-2125.2005.02481.x. Br J Clin Pharmacol. 2005. PMID: 16236049 Free PMC article. Review.
Anaphylactic Reaction to Tc-99m Macrosalb.
Schreuder N, de Hoog Q, van der Bruggen W, van Puijenbroek EP. Schreuder N, et al. Among authors: van puijenbroek ep. Drug Saf Case Rep. 2019 Mar 5;6(1):4. doi: 10.1007/s40800-019-0097-4. Drug Saf Case Rep. 2019. PMID: 30838475 Free PMC article.
Retroperitoneal fibrosis and β-blocking agents: Is there an association?
Kharagjitsing H, van Eekeren R, van Puijenbroek EP, van Gelder T, van Bommel EFH. Kharagjitsing H, et al. Among authors: van puijenbroek ep. Br J Clin Pharmacol. 2021 Jul;87(7):2891-2901. doi: 10.1111/bcp.14702. Epub 2021 Jan 9. Br J Clin Pharmacol. 2021. PMID: 33326117
The role of data mining in pharmacovigilance.
Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. Hauben M, et al. Among authors: van puijenbroek ep. Expert Opin Drug Saf. 2005 Sep;4(5):929-48. doi: 10.1517/14740338.4.5.929. Expert Opin Drug Saf. 2005. PMID: 16111454 Review.
Requirements for generic anti-epileptic medicines: a regulatory perspective.
Maliepaard M, Hekster YA, Kappelle A, van Puijenbroek EP, Elferink AJ, Welink J, Gispen-de Wied CC, Lekkerkerker FJ. Maliepaard M, et al. Among authors: van puijenbroek ep. J Neurol. 2009 Dec;256(12):1966-71. doi: 10.1007/s00415-009-5231-2. Epub 2009 Jul 15. J Neurol. 2009. PMID: 19603244 Free PMC article. Review. No abstract available.
197 results